<unk>  is a cholinesterase inhibitor that is FDA approved for the treatment of myasthenia gravis.   Common adverse reactions include diaphoresis, diarrhea, excessive salivation, increased peristalsis, nausea and vomiting, stomach cramps, muscle fasciculation, asthenia, miosis and excessive bronchial secretion.
Pyridostigmine
Physostigmine
Neostigmine
Neostigmine methylsulfate
Suxamethonium chloride
Thiocarboxime
Atropine 
Fomepizole